MedPath

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 3
Completed
Conditions
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Registration Number
NCT00003636
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.

PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.

Detailed Description

OBJECTIVES:

* Compare the overall survival and progression-free survival in patients with stage IIIC or IV ovarian epithelial, peritoneal, or fallopian tube carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery versus upfront cytoreductive surgery followed by chemotherapy with or without interval debulking surgery.

* Compare the quality of life of patients treated with these regimens.

* Compare the different treatment complications in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, method of biopsy, stage, largest tumor size before surgery, and intent to also randomize on EORTC-55012. Patients are randomized to one of two treatment arms.

* Arm I: Patients undergo upfront maximal cytoreductive surgery followed by cisplatin or carboplatin IV every 3 weeks for 3 courses. Patients with non-optimal primary debulking may undergo interval debulking surgery at the physician's discretion. All patients then receive an additional 3 courses of the same regimen of chemotherapy.

* Arm II: Patients receive chemotherapy as in arm I. Patients with stable or responding disease undergo interval debulking surgery followed by an additional 3 courses of the same regimen of chemotherapy.

Second-look surgery is allowed for both arms if clinically indicated.

Quality of life (QOL) is assessed prior to treatment, after the third and sixth course of chemotherapy, and at 6 and 12 months after study. Patients who are also randomized on EORTC-55012 follow the QOL assessment schedule for EORTC-55012 only.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 704 patients will be accrued for this study within 4 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
704
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival as measured by Kaplan Meier every 3 months for 2 years, every 6 months for 3 years, and then annually
Secondary Outcome Measures
NameTimeMethod
Progression-free survival as measured by Kaplan Meier and RECIST every 3 months for 2 years, every 6 months for 3 years, and then annually
Health-related quality of life as measured by Quality of Life Questionnaire-C30 after courses 1, 3 and 6, then at 6 and 12 months
Toxicity as measured by NCIC Common Toxicity Criteria v2.0 within 4 weeks of surgery

Trial Locations

Locations (65)

University College of London Hospitals

🇬🇧

London, England, United Kingdom

Doctor H. Bliss Murphy Cancer Centre

🇨🇦

St. Johns, Newfoundland and Labrador, Canada

Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital

🇦🇹

Vienna, Austria

BCCA - Fraser Valley Cancer Centre

🇨🇦

Surrey, British Columbia, Canada

Cazk Groeninghe - Campus Maria's Voorzienigheid

🇧🇪

Kortrijk, Belgium

Western Infirmary

🇬🇧

Glasgow, Scotland, United Kingdom

Allgemeines Krankenhaus - Universitatskliniken

🇦🇹

Vienna, Austria

Karolinska University Hospital - Huddinge

🇸🇪

Stockholm, Sweden

Libero Istituto Universitario Campus Bio-Medico

🇮🇹

Rome, Italy

Karl-Franzens-University Graz

🇦🇹

Graz, Austria

Hopital Charles Lemoyne

🇨🇦

Greenfield Park, Quebec, Canada

Shaare Zedek Medical Center

🇦🇷

Buenos Aires, Argentina

Innsbruck Universitaetsklinik

🇦🇹

Innsbruck, Austria

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Spedali Civili di Brescia

🇮🇹

Brescia, Italy

McGill Cancer Centre at McGill University

🇨🇦

Montreal, Quebec, Canada

Nova Scotia Cancer Centre

🇨🇦

Halifax, Nova Scotia, Canada

Hospital de Clinicas "Jose De San Martin"

🇦🇷

Buenos Aires, Argentina

Centre Oscar Lambret

🇫🇷

Lille, France

Vrije Universiteit Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Academisch Medisch Centrum at University of Amsterdam

🇳🇱

Amsterdam, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

Daniel Den Hoed Cancer Center at Erasmus Medical Center

🇳🇱

Rotterdam, Netherlands

Tom Baker Cancer Centre - Calgary

🇨🇦

Calgary, Alberta, Canada

CancerCare Manitoba

🇨🇦

Winnipeg, Manitoba, Canada

Centre Hospitalier Regional et Universitaire de Lille

🇫🇷

Lille, France

Academisch Ziekenhuis der Vrije Universiteit Brussel

🇧🇪

Brussels, Belgium

Cancer Centre of Southeastern Ontario at Kingston General Hospital

🇨🇦

Kingston, Ontario, Canada

CHUS-Hopital Fleurimont

🇨🇦

Fleurimont, Quebec, Canada

Hospital Universitario San Carlos

🇪🇸

Madrid, Spain

Hospital Universitario Central de Asturias

🇪🇸

Oviedo, Spain

St. James's Hospital

🇮🇪

Dublin, Ireland

James Cook University Hospital

🇬🇧

Middlesbrough, England, United Kingdom

Onze Lieve Vrouwe Gasthuis

🇳🇱

Amsterdam, Netherlands

Universitair Medisch Centrum St. Radboud - Nijmegen

🇳🇱

Nijmegen, Netherlands

Erasmus MC - Sophia Children's Hospital

🇳🇱

Rotterdam, Netherlands

Umea Universitet

🇸🇪

Umea, Sweden

Azienda Sanitaria Ospedaliera Ordine Mauriziano

🇮🇹

Torino, Italy

Institut Claudius Regaud

🇫🇷

Toulouse, France

Institut d'Oncologia Corachan

🇪🇸

Barcelona, Spain

Royal United Hospital

🇬🇧

Bath, England, United Kingdom

Akademisch Ziekenhuis Vrije Universiteit - Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Lund University Hospital

🇸🇪

Lund, Sweden

Haukeland Hospital - University of Bergen

🇳🇴

Bergen, Norway

Uppsala University Hospital

🇸🇪

Uppsala, Sweden

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospitais da Universidade de Coimbra (HUC)

🇵🇹

Coimbra, Portugal

Cheltenham General Hospital

🇬🇧

Cheltenham, England, United Kingdom

Clatterbridge Centre for Oncology NHS Trust

🇬🇧

Merseyside, England, United Kingdom

Mount Vernon Cancer Centre at Mount Vernon Hospital

🇬🇧

Northwood, England, United Kingdom

Queen Elizabeth The Queen Mother Hospital

🇬🇧

Margate, United Kingdom

Herlev Hospital - University Hospital of Copenhagen

🇩🇰

Copenhagen, Denmark

Mirano General Hospital

🇮🇹

Mirano-Venice, Italy

Clinica Universitaria

🇮🇹

Turin, Italy

Hopital Notre-Dame du CHUM

🇨🇦

Montreal, Quebec, Canada

Staffordshire General Hospital

🇬🇧

Stafford, England, United Kingdom

Martin Luther Universitaet

🇩🇪

Halle, Germany

Institut Bergonie

🇫🇷

Bordeaux, France

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Nottingham City Hospital NHS Trust

🇬🇧

Nottingham, England, United Kingdom

Coombe Women's Hospital

🇮🇪

Dublin, Ireland

Norwegian Radium Hospital

🇳🇴

Oslo, Norway

Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.

🇵🇹

Lisbon, Portugal

British Columbia Cancer Agency - Vancouver Cancer Centre

🇨🇦

Vancouver, British Columbia, Canada

Saint John Regional Hospital

🇨🇦

Saint John, New Brunswick, Canada

© Copyright 2025. All Rights Reserved by MedPath